Public Companies
The MindMed Chronicles: An Interview With Robert Barrow, the CEO of MindMed
The following is a continuation of all our recent MindMed coverage. Over the past few weeks, we published a few conversations with Jake Freeman. Click…
The following is a continuation of all our recent MindMed coverage.
Over the past few weeks, we published a few conversations with Jake Freeman.
Before that, it all began with a two-part interview with Dr. Scott Freeman in August.
A Conversation with the MindMed CEO, Robert Barrow
While we’ve had the pleasure of speaking with Freeman Captial on multiple occasions, we are just as excited to be joined by MindMed’s CEO, Robert Barrow, to help readers better understand their side of the story. This interview with Robert is only the beginning. We fully expect to have him back on again soon.
Stay Tuned for More
We expect to have Rob and others involved in this story back on to continue the narrative. Stick around for more interviews, in-depth analyses, and insights as the story progresses.
Follow the Psychedelic Invest YouTube Channel
As always, please like and subscribe to the Psychedelic Invest YouTube channel.
-
Psychedelics1 week agoCybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
-
Law & Regulation1 week agoGoing concern warnings cloud Xtacy Therapeutics’ shrunk losses
-
Psilocybin1 week agoAre Shrooms Legal in Oregon: Full Guide
-
Law & Regulation1 week agoNuminus reports declining revenue as the company restructures
-
Psychedelics1 week agoOptimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
-
Psychedelics1 week agoAtai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
-
Psychedelics1 week agoPsyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
-
Law & Regulation7 days agoClearmind signs agreement with Hebrew University for psychedelic compound rights